Functional assays further revealed that combining a VEGFR-2 inhibitor with erlotinib reduced the viability of EGFR double-mutant NSCLC cells (9%) significantly more than erlotinib alone (72%) [167]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.